Joint AABB-THOR Working Party Petition

The following individuals endorse the following statement:

“Do you agree that AABB standards should allow for uncrossmatched, low titer, group O WB to be used in the resuscitation of massively bleeding patients whose ABO group might not be known at the time of WB transfusion?”

1. **Sasha D Adams, MD**  
   UT Health, Houston. Asst Professor Surgery  
   6431 Fannin Street, MSB 4.282. Houston, TX 77030  
   sasha.d.adams@uth.tmc.edu

2. **Jason Acker, BSc MSc MBA PhD**  
   Senior Research Scientist - Canadian Blood Services  
   Professor - Laboratory Medicine and Pathology, University of Alberta  
   acker@blood.ca

3. **Louis Alarcon, MD, FACS, FCCM**  
   Professor of Surgery and CCM  
   Medical Director, Trauma Surgery  
   University of Pittsburgh School of Medicine  
   F-1264, UPMC-Presbyterian  
   200 Lothrop St.  
   Pittsburgh, PA 15213  
   412-647-1158  
   alarconl@upmc.edu

4. **Shubha Allard MD FRCP FRCPath**  
   Consultant Haematologist  
   Barts Health NHS Trust and NHS Blood and Transplant  
   shubha.allard@nhsbt.nhs.uk

5. **Arwa Z. Al-Riyami, BS.c, MD, FRCPC**  
   Senior Consultant Hematopathologist  
   Department of Haematology, Sultan Qaboos University Hospital  
   PO Box 38, PC 123, Muscat, Oman  
   arwa.alriyami@gmail.com

6. **Torunn Oveland Apelseth, MD, PhD**  
   Senior Consultant  
   Department of immunology and transfusion medicine  
   Haukeland University Hospital, N-5021 Bergen, Norway  
   torunn.oveland.apelseth@helse-bergen.no
7. **James P. AuBuchon, MD**  
Bloodworks  
921 Terry Ave, Seattle, WA 98104  
jima@bloodworksnw.org

8. **Sylvain Ausset MD**  
Professor & Chair of anaesthesia & intensive care  
HIA Percy. 92140 Clamart. France  
sylvain.ausset@gmail.com

9. **Ivar Austlid, MD**  
Anaesthesiologist Consultant  
Nordre Hauglandshella 31, 5314 Kjærgarden, Norway  
iaust@live.com

10. **Andrew N. Beckett, CD MD FRCS(C) FACS**  
Assistant Professor of Surgery, McGill University  
LTC, Royal Canadian Army Medical Corps  
Montreal General Hospital  
Andrew.beckett@mcgill.ca

11. **Rachel Beddard, MD**  
Medical Director, BioBridge Global  
6211 IH10 West, San Antonio, Texas 78201  
rachel.beddard@biobridgeglobal.org

12. **Alec C. Beekley, MD**  
Professor of Surgery, Sidney Kimmel Medical College at Thomas Jefferson University  
1100 Walnut Street, Philadelphia, PA 19107  
alec.beekley@jefferson.edu

13. **LTC Carmen Bell**  
Deputy for Operations  
US Armed services blood procurement office

14. **SGT Vincent Bennell**  
4 Pages Close, Wymondham, Norfolk, NR18 OTU  
vmbennell@yahoo.co.uk

15. **Olle Berséus, MD, PhD**  
Specialist in Transfusion Medicine  
FoU Department, Örebro University Hospital, Örebro, Sweden  
Consultant in transfusion Medicine to the Swedish Armed Forces.  
Örtenlundsv. 7, 702 30 Örebro, Sweden  
berseus@telia.com
16. **Marsha Bertholf, M.D.**
   Medical Director
   Gulf Coast Regional Blood Center
   mbertholf@giveblood.org

17. **Kenneth A. Bertram, MD PhD FACP**
   Principal Assistant for Acquisition
   US Army Medical Research and Materiel Command
   Ft Detrick, MD 21702
   kenneth.a.bertram.civ@mail.mil

18. **Per Olav Berve, MD**
   Consultant anaesthesist
   Oslo University Hospital, air amb div
   Lysgata 14, 1482 Nittedal
   poberve@gmail.com

19. **Charlene Bierl, MD, PhD**
   Director of the Clinical Laboratory
   Cooper University Hospital
   Camden, NJ 08103
   bierl-charlene@CooperHealth.edu

20. **Geir Bjerkan, MD, PHD**
    St. Olavs University Hospital and Norwegian Armed Forces, Joint Medical Services
    Dalhaugveien 53, 7020 Trondheim
    gbjerkan@hotmail.com

21. **Christopher Bjerkvig, MD**
    Norwegian Special Forces Medical Service
    Christopherbjerkvig@me.com

22. **Neil Blumberg, MD**
    Professor of Laboratory Medicine
    Director of Transfusion Medicine / Blood Bank
    University of Rochester Medical Center
    Neil_Blumberg@urmc.rochester.edu

23. **COL Milos Bohonek, MD, PhD**
    Military University Hospital Prague, Czech Republic
    U Vojenske nemocnice 1200, 16902 Prague, Czech Republic
    milos.bohonek@uvn.cz
24. **Matthew A. Borgman, MD, FCCM, CHSE**  
   Chief, Pediatric Critical Care Services  
   Medical Director, BAMC Simulation Center  
   Associate Professor of Pediatrics, Uniformed Services University  
   Brooke Army Medical Center  
   MCHE-ZDP/PICU  
   3551 Roger Brooke Dr.  
   JBSA Ft. Sam Houston, TX 78234  
   matthew.a.borgman.mil@mail.mil

25. **LT COL Matt Boylan, FRCEM RAMC**  
   Consultant Advisor PHEM (British Army)  
   RCDM, Birmingham. UK  
   m.boylan@nhs.net

26. **Marshall Keith Brown, DO**  
   FAAFP; A. Prof UNMC, Medical Director Alpha Medical Inc.  
   401 E 8th St Ste 214-953, Sioux Falls SD 57103  
   drkeithbrown@gmail.com

27. **Michael P. Busch, MD, Ph.D.**  
   Director, Blood Systems Research Institute  
   Senior Vice President, Blood Systems  
   Professor of Laboratory Medicine, UCSF  
   mbusch@bloodsystems.org

28. **Becky Butler Cap, MBA**  
   Chief Operating Officer, South Texas Blood and Tissue Center  
   6211 IH 10 West, San Antonio, TX 78201  
   becky.cap@gencure.org

29. **Frank K. Butler, MD**  
   CAPT MC USN (ret)  
   Chairman, Committee on TCCC  
   Chief, Prehospital Trauma Care, Joint Trauma System  
   Adjunct Professor of Military and Emergency Medicine  
   Uniformed Services University of the Health Sciences  
   4575 Lavallet LnPensacola, Florida 32504  
   fkb064@yahoo.com

30. **David Callaway, MD**  
   Director, Division of Operational and Disaster Medicine  
   Associate Professor, Emergency Medicine  
   Department of Emergency Medicine, Carolinas Medical Center  
   1528 Dilworth Rd, Charlotte, NC 28203  
   dcallawa@gmail.com
31. **Jose Cancelas-Perez, MD**  
   Director, Research Division and Medical Director for Cell Therapies, Hoxworth Blood Center  
   Deputy Director, Hoxworth Blood Center  
   Leader, Stem Cell Program  
   Incumbent, Beatrice C. Lampkin Endowment for Stem Cell and Hematotherapy  
   Cincinnati Children’s  
   Jose.Cancelas@cchmc.org

32. **Jeremy W. Cannon, MD, SM**  
   Associate Professor of Surgery, University of Pennsylvania  
   51 N. 39th Street, MOB 120 Philadelphia, PA 19104  
   jeremy.cannon@uphs.upenn.edu

33. **COL Andrew P. Cap, MD, PhD, FACP**  
   Medical Corps, US Army  
   Chief, Blood Research, US Army Institute of Surgical Research  
   Medical Director, Akeroyd Blood Donor Center  
   Associate Professor of Medicine, Uniformed Services University  
   Program Director, Clinical Research Fellowship  
   Deputy Hematology-Oncology Consultant to the Surgeon General  
   Staff Hematologist-Oncologist, San Antonio Military Medical Center  
   andrew.p.cap.mil@mail.mil

34. **D. Joe Chaffin, MD**  
   VP/Chief Medical Officer  
   LifeStream Blood Bank, San Bernardino, CA  
   Creator and Editor, BBGuy.org  
   joe.chaffin@bbguy.org

35. **Jill M Cholette, MD**  
   Associate Professor of Pediatrics  
   University of Rochester  
   Rochester NY  
   Jill_Cholette@URMC.Rochester.edu

36. **Joan Cid, MD, PhD**  
   Apheresis & Cellular Therapy Unit  
   Department of Hemotherapy and Hemostasis, ICMHO  
   Hospital Clinic  
   Villarroel 170  
   08036 Barcelona (Catalonia, Spain)  
   jcid@clinic.cat
37. Franklyn Cladis, MD FAAP
   Associate Professor of Anesthesiology
   Program Director,
   Pediatric Anesthesiology Fellowship
   The Children's Hospital of Pittsburgh of UPMC
   CladFP@UPMC.EDU

38. Claudia S. Cohn, MD, PhD
   Associate Professor
   Medical Director, Blood Bank
   Associate Head of Clinical Laboratories
   University of Minnesota
   cscohn@umn.edu

39. Brian Cornelius DNP CRNA NRP
   University Health-Shreveport
   1541 Kings Hwy Shreveport LA 71103
   Brian.cornelius@uhsystem.com

40. LTC Jason B. Corley
    Deputy Director, Army Blood Program
    jason.b.corley.mil@mail.mil

41. Brian Cornelius, DNP CRNA NRP
    University Health
    9422 Milbank Dr Shreveport, LA 71115
    Brian.cornelius@uhsystem.com

42. Bryan A. Cotton, MD, MPH
    Professor of Surgery and The John B Holmes Professor of Clinical Sciences
    Director, Surgical Critical Care, Acute Care Surgery and Trauma Fellowships
    Department of Surgery and The Center for Translational Injury Research
    McGovern Medical School at The University of Texas Health Science Center
    Houston, Texas
    Bryan.A.Cotton@uth.tmc.edu

43. Jon B. Christensen, APA-C, HMO, FAWM, DiMM
    Chief of Medical Training for International Special Training Centre/ OIC of NATO Special
    Operations Combat Medic course.
    CMR 445 Box GD. ISTC APO, AE 09046
    Medchief@istc-sof.org

44. Melissa Cushing, MD
    Associate Professor/Weill Cornell Medicine/NewYork-Presbyterian Hospital
    525 East 68th St, Box 251, Blood Bank, NY, NY 10065
    mec2013@med.cornell.edu
45. **Robertson D. Davenport, MD**  
   Professor of Pathology  
   Director, Transfusion Medicine  
   University Hospital 2G332/5054  
   1500 E. Medical Center Dr.  
   Ann Arbor, MI 48109-5054  
   rddvnpnt@umich.edu

46. **Vincenzo De Angelis, MD**  
   Director Transfusion Medicine Dept.  
   Azienda Sanitaria Universitaria Integrata  
   S. Maria della Misericordia" - UDINE  
   P.le S. Maria della Misericordia, 15 - 33100 UDINE (Italy)  
   vincenzo.deangelis@asuiud.sanita.fvg.it

47. **Meghan Delaney, DO**  
   Chief, Pathology & Laboratory Medicine  
   Children’s National Health System  
   111 Michigan Ave NW  
   Washington DC, 20010  
   mdelaney2@childrensnational.org

48. **Gregory A Denomme, PhD, FCSMLS(D)**  
   Senior Investigator, Blood Research Institute  
   Senior Director, Immunohematology and Innovation  
   BloodCenter of Wisconsin  
   638 N 18th Street  
   PO Box 2178  
   Milwaukee, WI 53201-2178  
   Gregory.Denomme@BCW.edu

49. **Marc De Pasquale, BS**  
   18D Special Forces Medic  
   Paramedic NREMT  
   Deployment Medicine International  
   mxdpx@yahoo.com

50. **Allan Doctor, MD**  
   Washington University in St. Louis / Professor of Pediatrics and Biochemistry  
   Campus Box 8208 / 660 S Euclid Street / Saint Louis, MO / 63108  
   doctor@wustl.edu
51. **Thomas Dolven, MD**  
Consultant in Anesthesia and Intensive Care  
Kalfarveien 108A, 5022 Bergen, Norway  
thomasdolven@gmail.com

52. **Heidi Doughty, MD MBA FRCP FRCPath**  
Consultant in Transfusion Medicine  
NHS Blood and Transplant  
UK

53. **Leilani Doyle, BSc MSc MD**  
Associate Professor University of Ottawa, Royal Canadian Medical Corp Anesthesiologist  
411 Ravenhill Ave Unit C K2A0J7  
ldoyle@Ottawahospital.on.ca

54. **Larry J. Dumont, MBA, PhD**  
Associate Director and Senior Investigator  
Blood Systems Research Institute – Denver  
c/o Bonfils Blood Ctr.  
717 Yosemite Street  
Denver, CO 80230Office: 303-363-2401  
ldumont@bloodsystems.org

55. **Nancy M. Dunbar, MD**  
Associate Professor  
Geisel School of Medicine  
Department of Pathology and Laboratory Medicine  
Department of Medicine  
Medical Director, Blood Bank  
Associate Medical Director, Transfusion Medicine Service  
Nancy.M.Dunbar@hitchcock.org

56. **David Duncan, MD**  
Medical Director: CALSTAR Air Ambulance, Medical Director: CAL FIRE  
6952 Kayo Drive, Penryn, CA 95663  
daveduncanmd@gmail.com

57. **Richard P. Dutton, MD MBA**  
Chief Quality Officer, US Anesthesia Partners  
Dallas, TX  
Richard.dutton@usap.com

58. **Torsten Eken, MD PhD**  
Consultant anaesthesiologist, Oslo University Hospital, and Researcher in traumatology  
University of Oslo  
Oslo University Hospital Ullevål, Dept. of anaesthesiology  
PO Box 4956 Nydalen, NO-0424 Oslo, Norway  
torsten.eken@medisin.uio.no
59. **Håkon Eliassen**  
   Norwegian Special Forces Medical Service  
   Norway  
   hskogran@hotmail.com

60. **CAPT Roland Fahie**  
   Director, US Armed Services Blood Procurement Office

61. **Andrew D. Fisher, MPAS, PA-C**  
   PA-C, US Army Reserve, Major  
   andrewdfisher@icloud.com

62. **G. Michael Fitzpatrick, PhD, COL (Ret.) USA**  
   President  
   Director Clinical Research and Development, Cellphire Inc.  
   9430 Key West Ave Suite 204  
   Rockville. MD 20850  
   mfitzpatrick@cellphire.com

63. **Steven M. Frank, MD**  
   Director PBM Program / Johns Hopkins / Professor  
   1800 Orleans Street, Zayed 6208, Baltimore, MD 21287  
   sfrank3@jhmi.edu

64. **Alan I. Frankfurt, MD**  
   Anesthesiologist  
   7626 Caillet Street  
   F7040@aol.com

65. **Barbara A. Gaines, MD**  
   Professor of Surgery  
   University of Pittsburgh School of Medicine  
   Director, Trauma and Injury Prevention  
   Clinical Director, Division of General and Thoracic Surgery  
   Program Director, Pediatric Surgery Training Program  
   Children’s Hospital of Pittsburgh of UPMC  
   gainesba@upmc.edu

66. **Pr. Olivier Garraud, MD PhD**  
   Senior Consultant  
   International Affairs  
   INTS - Institut National de la Transfusion Sanguine  
   6 rue Alexandre-Cabanel - 75739 PARIS cedex 15 - France  
   ogarraud@ints.fr
67. **Eric A. Gehrie, MD**  
Assistant Professor, Pathology  
Johns Hopkins University  
Associate Director, Transfusion Medicine  
Johns Hopkins Hospital  
egehrie1@jhmi.edu

68. **Karen Giordano**  
KGiordano@cerus.com

69. **Melissa Givens, MD MPH**  
Associate Professor Department of Military and Emergency Medicine, Uniformed Services University  
4117 Jones Bridge Road, Chevy Chase MD  
melissa.givens@usuhs.edu

70. **Jacob Glaser, MD**  
Critical Care and Trauma Surgeon, Naval Medical Research Unit San Antonio  
3503 Puesta De Sol San Antonio TX 78261  
jacob.glaser1@gmail.com

71. **COL Elon Glassberg, MD**  
Professor of Surgery  
IDF medical corps headquarters, Israel  
edoc11@gmail.com

72. **Sherry Glenn, CLS(ASCP)SBB**  
Major  
311 Foxglove Path, San Antonio, TX 78245  
Sherry.d.glenn.mil@mail.mil

73. **Ruchika Goel, MD MPH**  
New York Presbyterian Hospital, Weill Cornell Medicine, Assistant Medical Director of TM/CT, Assistant professor  
525 East 68th Street, M-014, New York Presbyterian Weill Cornell.  
ruchikagoel1@gmail.com

74. **Samantha Gomez Ngamsuntikul, MD**  
Associate Medical Director  
6211 IH 10 W, San Antonio TX 78201  
samantha.ngamsuntikul@biobridgeglobal.org

75. **Richard Gonzales, MS**  
Director, TerumoBCT, COL, US Army, MT(ASCP)SBB  
440 Devine Road, Olmos Park, TX 78212  
Richard.gonzales@terumobct.com
76. **Dr Laura Green, MBBS, MD(Res), FRCP, FRCPath**  
Barts Health NHS Trust and NHS Blood and Transplant, London, United Kingdom  
laura.green@bartshealth.nhs.uk

77. **Ronald I. Gross, MD, FACS**  
Chief, Division of Trauma, Acute Care Surgery & Surgical Critical Care Baystate Medical Center  
759 Chestnut Street, Springfield, MA 01199  
ronald.gross@baystatehealth

78. **James Richard Gruenewald APA-C, MPAS**  
Deputy Regiment Surgeon/160th Special Operations Aviation Regiment (Abn)/Captain  
1149 North Ja Tate Drive Clarksville, TN 37043  
jimmygruenewald@gmail.com

79. **Mark W. Hall, MD**  
Chief, Division of Critical Care Medicine, Nationwide Children's Hospital  
Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH. 43205  
Mark.Hall@nationwidechildrens.org

80. **Judith Hannon, MD FRCPC**  
Medical Officer, Canadian Blood Services, Edmonton, Alberta, Canada  
Clinical Professor, University of Alberta, Edmonton, Alberta, Canada  
8249-114 Street, Edmonton, Alberta, Canada, T6G 2R8  
judy.hannon@blood.ca

81. **Sheila J. Hanson, MD, MS**  
Associate Professor of Pediatrics  
Associate Director, PICU  
Children's Hospital of Wisconsin  
shanson@mcw.edu

82. **Sarah K Harm, MD, MS**  
Assistant Professor, Pathology  
Robert Larner, M.D. College of Medicine @ UVM  
Medical Director, Blood Bank  
University of Vermont Medical Center  
233 MP1, 111 Colchester Ave, Burlington, VT 05401

83. **John Andrew Harvin, MD**  
Assistant Professor, UT Health  
6431 Fannin Street, MSB 4.294 Houston, TX 77030  
John.Harvin@uth.tmc.edu
84. Tor Hervig, MD  
Overlege  
Helse Førde HF  
Norway  
tor.audun.hervig@helse-bergen.no

85. Luis Alfredo Perez Bolde Hernandez  
Lieutenant Col. Medicina Tactica Mexcio  
calle cantil 31 D fracc.cañada de la bufa, guadalupe Zacatecas C.P. 98613 mexico  
director@medtacmex.org.mx, hypermed@gmail.com

86. CDR Jonathan Hoiles, MSC, USN  
Branch Head, Navy Blood Program

87. John Holcomb, MD  
Professor of Surgery, UT Health, Houston TX  
Suite 1100, 6410 Fannin, Houston, TX, 77030  
john.holcomb@uth.tmc.edu

88. Eirik Holmstrøm, EMT-P/Flight P/CCATT MCD  
AOIC-Instructor / ISTC NSOCM /CPT  
Passebekkv. 546, 3648 Passebekk, Norway  
eirik@holmy.no

89. Greggory J. Housler, MScEng, MBA  
Product Manager, Blood Products  
US Army Medical Materiel Development Activity (USAMMDA) Pharmaceutical Systems  
Program Management Office (PSPMO)  
1430 Veterans Drive, Room 312  
Fort Detrick, MD 21702-5009  
greggory.j.housler.civ@mail.mil

90. Beverley J Hunt, FRCP, FRCPath, MD  
Thrombosis & Haemostasis, King's College  
Consultant, Depts of Haematology & Pathology,  
Clinical Lead in Haematological Laboratories  
Guy's & St Thomas' NHS Foundation Trust & Viapath  
Westminster Bridge Road  
London SE1 7EH  
Beverley.Hunt@gstt.nhs.uk

91. Fabian Hurbín  
NR-P / Lieutenant  
Weidstrasse 27, CH-4317 Wegenstetten, Switzerland  
fabian.huerbin@vtg.admin.ch
92. **Donald H. Jenkins, MD, FACS**  
Professor/Clinical, Division of Trauma and Emergency Surgery  
Vice Chair for Quality, Department of Surgery  
Betty and Bob Kelso Distinguished Chair in Burn and Trauma Surgery  
Associate Deputy Director, Military Health Institute  
UT Health San Antonio  
7703 Floyd Curl Drive  
San Antonio, TX 78229-3900  
Jenkinsd4@uthscsa.edu

93. **Bryon P. Jackson Sr., MD, MHA**  
Assistant Professor of Pathology  
Emory University School of Medicine  
Medical Director Blood and Transfusion Services  
Grady Memorial Hospital  
bryon.patrick.jackson@emory.edu

94. **Timo Jama, MD, MSc (disaster medicine)**  
Medical Director of EMS  
Keskussairaalankatu 7, 15850 Lahti, FINLAND  
timo.jama@phhyky.fi

95. **Dennis Jarema, 18D RN**  
18D/ USSOCOM/ SSG  
2103 Stonewall Farms dr  
dmjarema@hotmail.com

96. **David Jobes, MD**  
Professor of Anesthesia and Critical Care; the Children's Hospital of Philadelphia and the Perelman  
School of Medicine at the University of Pennsylvania  
the Children's Hospital of Philadelphia; 34th Civic Center Blvd; Phila. PA  
jobes@email.chop.edu

97. **George A. Johnson, MSN**  
Landstuhl Regional Medical Center/212th Combat Support Hospital/LTC  
CMR 422, BOX 398, APO, AE 09067  
george.johnson1900@gmail.com

98. **Cassandra D. Josephson, MD**  
Professor, Pathology and Pediatrics, Emory University School of Medicine  
Director of Clinical Research, Center for Transfusion and Cellular Therapies  
Program Director, Transfusion Medicine Fellowship  
Medical Director, Children's Healthcare of Atlanta Blood, Tissue, and Apheresis Services, Atlanta, GA  
cjoseph@emory.edu
99. **Antti Kämäräinen, MD, PhD**  
Assistant chief physician, prehospital emergency medical services & HEMS  
Tempere University Hospital  
Finland  
Antti.kamarainen@pshp.fi

100. **Shawn F. Kane, MD FAAFP, FACSM**  
COL, MC, MFS, DMO  
Commander, Special Warfare Medical Group (Airborne)  
Dean, Joint Special Operations Medical Training Center  
Family Medicine Consultant to The Surgeon General  
shawn.kane@socom.mil

101. **Matthew S. Karafin, MD, MS**  
BloodCenter of Wisconsin  
638 N 18th Street, Milwaukee WI 53201  
matthew.karafin@bcw.edu

102. **Oliver Karam, MD, PhD**  
Children's Hospital of Richmond at VCU  
1250 E Marshall St, Richmond, VA 23298  
oliver.karam@vcuhealth.org

103. **Jeffry Kashuk, MD**  
Professor of Surgery, Tel Aviv- Sackler SOM  
Habarzel 11 Suite 5A TelAviv Israel  
Jeffrykashuk@gmail.com

104. **Louis M. Katz, MD**  
Interim Chief Executive Officer  
Chief Medical Officer  
America's Blood Centers  
725 15th St. NW, suite 700  
Washington DC, 20005  
Adjunct Clinical Professor  
University of Iowa, Carver College of Medicine, Division of Inf. Dis.  
lkatz@americasblood.org

105. **Sean Keenan, MD, FAAEM FAWM**  
US Special Operations Command  
USA  
dockeenan95@aol.com

106. **Jeffrey D. Kerby, MD, PhD**  
Professor and Director, Acute Care Surgery, University of Alabama at Birmingham  
KB 120, 1720 2nd Avenue South, Birmingham, Alabama 35294-0016  
jkerby@uabmc.edu
107. **Harvey G. Klein, MD**  
Chief, Department of Transfusion Medicine  
Clinical Center  
National Institutes of Health  
Adjunct Professor of Medicine and Pathology  
The Johns Hopkins School of Medicine

108. **Fredrik Koller Lund, MD EDIC**  
Consultant intensivist/anesthesiologist  
Haukeland University Hospital, 5021 Bergen, Norway  
fredrik.koller.lund@gmail.com

109. **Justina Kordai Ansah, MCChB, CTM, FGCPs**  
National Blood Service Ghana- Chief Executive Officer (C.E.O)  
National Blood Service Ghana  
GHANA  
kordaiansah@yahoo.com

110. **Rosemary Kozar, MD PhD**  
Professor of Surgery; Shock Trauma Center; University of Maryland  
22 South Green St. Maryland, MD 21201  
rkozar@umm.edu

111. **Robert Kramer, MD, FACS**  
Clinical Associate Professor of Surgery; Tufts University School of Medicine  
Maine Medical Center 22 Bramhall St Portland Maine  
kramer@mmc.org

112. **Oliver Kreuzer**  
SAR Flight Paramedic, Air Zermatt / Flight Paramedic US ARMY Reserve  
Heliport, 3920 Zermatt, Switzerland  
oliver.kreuzer@air-zermatt.ch

113. **Einar K. Kristoffersen, MD, PhD**  
Head of Department, Professor Univ. of Bergen  
Department of Immunology and Transfusion Medicine, Bergen, Norway  
einar.kristoffersen@helse-bergen.no

114. **Jens Kronborg, MD, PhD**  
Chief Consultant, Dept of Immunology and Transfusion Medicine, Innlandet Hospital, Norway  
Avd for blodbank og medisinsk biokjemi, Sykehuset Innlandet, 2629 Lillehammer, Norway  
kronborg@bbnett.no

115. **John Lacroix, 68W**  
US Army/68W/CoTCCC  
1111 vista Valet SATX 78216  
Jlcjohn83@gmail.com
116. **Sami Länkimäki**  
South-Ostrobothnian Health Care District /M.D, Chief Physician for Prehospital Care  
EPSHP, Ensihoitokeskus, Sami Länkimäki, Rengastie 13, 60100 Seinäjoki, Finland  
Sami.lankimaki@epshp.fi

117. **Marcus Larsson, MD MSc**  
Sunderby Hospital, Norrbotten County, Sweden  
Havrevagen 20, 95432 Gammelstad, Sweden  
marcus.o.c.larsson@gmail.com

118. **Fiona Lecky MB ChB, Ph D, FRCEM, FRCS**  
University of Sheffield and Salford Royal/Clinical Professor & Honorary Consultant  
CURE, HSR Section, School of Health and Related Research, University of Sheffield, Regent's Court, Regent Street, Sheffield S14DA  
f.e.lecky@sheffield.ac.uk

119. **Parvez M. Lokhandwala, MBBS, PhD**  
Assistant Professor, Division of Transfusion Medicine, Johns Hopkins University School of Medicine  
550 N. Broadway Building, 8th Floor, Baltimore, MD 21205  
PLOKHAN1@JHMI.EDU

120. **Paul Loos 18D**  
JSOMTC Instructor  
70 West Trafalgar Court  
medguy21@gmail.com

121. **Joseph Love, DO MS FACS**  
Associate Professor  
6431 Fannin Street Houston texas  
joseph.d.love@uth.tmc.edu

122. **Andrew I.R. Maas, MD, PhD**  
Em Professor of Neurosurgery  
University Hospital Antwerp  
Wilrijkstraat 10  
2650 Edegem - Belgium  
andrew.maas@uza.be

123. **Professor Dr. med. Marc Maegele**  
Klinik für Unfallchirurgie und Orthopädie  
Klinikum Köln-Merheim (Cologne-Merheim Medical Center)  
Universität Witten-Herdecke  
Institut für Forschung in der Operativen Medizin (IFOM)  
Ostheimerstr. 200, 51109 Köln  
Marc.Maegele@t-online.de
124. **Kathryn Maitland**  
Professor Paediatrics, Imperial College, London  
KEMRI Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya  
k.maitland@imperial.ac.uk

125. **Justin D. Manley, MD**  
Major  
809 Flowering Path, Niceville, FL 32578  
docmanley@gmail.com

126. **COL Elizabeth Mann-Salinas, PhD, RN**  
US Army Institute of Surgical Research, Colonel  
335 Pershing Ave San Antonio, TX 78309  
Elizmann@gmail.com

127. **Prof. Noga Manny, MD**  
Emeritus Associate Clinical Prof. of Internal Medicine (Hematology)  
Hebrew University ,Jerusalem ,Israel.  
Emeritus Medical Director of Hadassah Medical Center Blood Banks  
Jerusalem ,Israel

128. **Marisa B. Marques, MD**  
Transfusion Services Medical Director/UAB/ Professor of Pathology  
619 19th Street South/P230G/Birmingham/AL 35233  
mmarques@uabmc.edu

129. **Larry Martin, MD**  
University of Mississippi Medical Center  
2500 N. State St. Jackson, MS 39216  
lmartin3@umc.edu

130. **Elisabeth Maurer, PhD**  
Clin. Associate Prof., University of British Columbia; Chief Technology Officer, LightIntegra Technology Inc.  
330-2285 Clark Drive, Vancouver, BC, V5N 3G9  
emaurer@lightintegra.com

131. **Jeffrey McCullough, MD**  
Emeritus Prof university of Minnesota  
7400 Shannon Dr Edina MN 55439  
mccul002@umn.edu
132. **Michael T. Meyer, MD, MS**  
Chief, Pediatric Critical Care/Medical College of Wisconsin/Associate Professor  
9000 West Wisconsin Avenue, M.S. #681 Milwaukee, WI 53226  
mtmeyer@mcw.edu  
Timothy Miller MB ChB FRCA  
Associate Professor of Anesthesiology  
Chief, Division of General, Vascular and Transplant Anesthesia  
Director, Perioperative Medicine Fellowship  
Duke University School of Medicine  
timothy.miller2@duke.edu

133. **Ethan A Miles, MD**  
LTC, US Army  
Associate Professor, Uniformed Services University of the Health Sciences  
ethanamiles@yahoo.com

134. **Ernest E Moore, MD**  
University of Colorado Denver/Surgery/Professor  
Journal of Trauma, 655 Broadway, Denver 80203  
ernest.moore@dhha.org

135. **David S. Morris, MD**  
5161 S. Cottonwood St. Murray UT 84107  
davidstephenmorris@gmail.com

136. **Johan Storm Munch, MD**  
LtCol  
OPSTØ/Hæren, N-9325 Bardufoss, NORWAY  
johmunch@bbnett.no

137. **Alan Murdock, MD**  
Chief of Emergency Surgery, Allegheny General Hospital, Pittsburgh PA  
320 E North Ave, 5th Fl South Tower, Suite 594  
Alan.murdock@ahn.org

138. **Jennifer A Muszynski, MD, MPH**  
Assistant Professor of Pediatrics, Division of Critical Care Medicine, Nationwide Children's Hospital and The Ohio State University College of Medicine  
700 Children's Drive, Columbus Ohio 43205  
jennifer.muszynski@nationwidechildrens.org
139. **Lena M. Napolitano, MD, FACS, FCCP, MCCM**
Massey Foundation Professor of Surgery
Division Chief, Acute Care Surgery
Director, Trauma and Surgical Critical Care
Acute Care Surgery  [Trauma, Burn, Critical Care, Emergency Surgery]
Department of Surgery
University of Michigan Health System
lenan@umich.edu

140. **Matthew D. Neal, MD**
Assistant Professor of Surgery and Critical Care Medicine
Attending Surgeon, Division of Trauma and Acute Care Surgery
University of Pittsburgh Medical Center
F1271.2 PUH 200 Lothrop Street
Pittsburgh, PA 15213
nealm2@upmc.edu

141. **Marianne Nellis, MD, MS**
Assistant Professor
525 East 68th St, M512, NY, NY 10065
man9026@med.cornell.edu

142. **Andrea Neisser-Svae, PhD**
Octapharma, Head of Business Unit ICEM
Oberlaaerstrasse 235, A-1100 Vienna, Austria
andrea.neisser-svae@octapharma.com

143. **Paul M Ness, MD**
Director, Transfusion Medicine; Professor of Pathology and Medicine; Johns Hopkins Medical Institutions
Zayed 3081; Johns Hopkins Hospital: Baltimore MD 21287
pness@jhmi.edu

144. **Adrian Newland, CBE MA FRCP FRCPath**
Professor of Haematology
The Royal London Hospital
Barts Health NHS Trust
Pathology and Pharmacy Building
80, Newark Street
London, E1 2ES
a.c.newland@qmul.ac.uk

145. **Philip Norris, MD**
Senior Investigator
270 Masonic Ave., San Francisco, CA 94118
pnorris@bloodsystems.org
146. **COL (R) Adam Olszewski, MD**  
Deputy Director Of Military Blood Center  
00-671 Warsaw, Koszykowa 78  
zdyrmed@wckik.pl  
Poland

147. **E. Mary O'Neill, MD**  
180 Rustcraft Rd, Dedham, Mass 02026  
Mary.oneill@redcross.org

148. **Yaacov Orlin, MD**  
Director of the Dept. of Transfusion Medicine  
Maayane Hayeshua Medical Center  
Bnei Brak, Israel  
jerorlin@gmail.com

149. **Anand Padmanabhan, MD PhD QIA**  
Medical Director, BloodCenter of Wisconsin  
Associate Professor, Medical College of Wisconsin  
Associate Investigator, Blood Research Institute  
8733 Watertown Plank Road  
Milwaukee, WI 53226-3548  
anand.padmanabhan@bcw.edu

150. **Pierre Pasquier, MD**  
HIA PERCY 101 avenue Henri Barbusse 92141 CLAMART  
France  
pasquier9606@me.com

151. **Heather Pidcoke, MD PhD**  
Director, Global Clinical Safety&PRT Scientific Affairs/TerumoBCT  
10810 West Collins Avenue, Lakewood, CO 80215  
heather.pidcoke@terumobct.com

152. **Dr.med. Urs Pietsch / DESA / EDIC**  
Kantonsspital St.Gallen, Switzerland  
Institute of Anaesthesiology & Intensive Care Medicine, Air  
Zermatt, Switzerland , Consultant ICU  
Air Zermatt, Heliport Raron, Switzerland  
pietsch@gmx.de

153. **Timothy A Pritts, MD, PhD**  
Professor of Surgery, University of Cincinnati  
231 Albert Sabin Way, ML 0558, Cincinnati, Ohio 45268  
prittsta@ucmail.uc.edu
154. **CPT Nadir Rachedi, MD**  
Anesthesiologist and Intensive Care Physician  
Military Hospital Rome  
livorno187@gmail.com

155. **Naomi Rahimi-Levene, MD**  
Director of the Blood Bank, Assaf Harofeh Medical Center, Zerifin, Israel  
Member of the Transfusion Medicine Advisory Board to the Ministry of Health in Israel  
Head of the Israeli Transfusion Medicine Study Group  
nrlevene@asaf.health.gov.il

156. **Joseph Rappold, MD, FACS**  
CAPT MC USN (Ret); Chief, Acute Care Surgery  
Trauma Medical Director, Department of Surgery  
Tufts University School of Medicine  
Maine Medical Center  
jrappold@mmc.org

157. **Jørn E Rasmussen**  
Head of ED  
Specialist in Internal medicine and Cardiologi.  
Drammen Hospital Trust, Vestre Viken HF | www.vestreviken.no  
Major, MD in Norwegian Armjed Forces.  
Call: 7675  
Mobilnr: +47 91720615  
rasj@vestreviken.no

158. **Jay S. Raval, MD**  
Assistant Professor  
Department of Pathology and Laboratory Medicine  
Director of Therapeutic Apheresis and Blood Donor Center  
Associate Director of HPC Laboratories  
jay_raval@med.unc.edu

159. **COL Michael Reade, MBBS MPH DPhil DMedSc FANZCA FCICM**  
Level 9 Health Sciences Bldg, Royal Brisbane & Women’s Hospital 4029  
Australia  
m.reade@uq.edu.au

160. **LT COL Rich Reed, FRCA RAMC**  
16 Medical Regiment, Defence Medical Services, UK  
Anaesthetist Department, Derriford Hospital, Plymouth, PL6 8DH, UK  
richard.reed1@nhs.net
161. **Oliver Reisten, PhD**  
Medical Director of Rescue Service Solothurn Hospitals, Consultant in Anaesthesia and Emergency Medicine  
Allmendstrasse 61, CH-4612 Wange bei Olten, Switzerland  
oliver.reisten@air-zermatt.ch

162. **Kenneth E. Remy, MD, MHSc**  
Washington University in St. Louis  
1 Children's Place St. Louis, MO 63005  
kremy@wustl.edu

163. **Peter Rhee, MD, MPH, FACS, FCCM**  
Senior Vice President  
Chief of Acute Care Surgery and Trauma Medical Director  
Grady Memorial Hospital  
80 Jesse Hill Jr. Drive SE, Atlanta, Georgia 30303  
prhee@GMH.EDU

164. **John D. Roback, MD, PhD**  
Professor of Pathology and Laboratory Medicine  
Medical Director, Emory Medical Laboratories  
Vice-Chair, Clinical Pathology and Laboratory Medicine  
Director, Center for Transfusion and Cellular Therapies  
Emory University School of Medicine  
EUH D-655, 1364 Clifton Rd NE  
Atlanta, GA 30322  
jroback@emory.edu

165. **Susan N. Rossmann, MD, PhD**  
Chief Medical Officer  
Gulf Coast Regional Blood center  
Houston TX  
rossman@giveblood.org

166. **Nareg Roubinain, MD**  
Clinical investigator  
Blood systems research institute  
Nareg.Roubinian@ucsf.edu

167. **Rob Russell, MD, MPH**  
Assistant Professor of Pediatric Surgery  
Children's of Alabama  
University of Alabama at Birmingham  
1600 7th Ave. S., Lowder Building Suite 300  
Birmingham, AL 35233  
Robert.Russell@childrensal.org
168. **Anne Sailliol**  
physician, specialist in hemobiology and transfusion expert.  
Clamart.  
France  
anne.sailliol@wanadoo.fr

169. **Thomas M. Scalea, MD**  
Physician in Chief,  
R Adams Cowley Shock Trauma Center  
Francis X Kelly Distinguished Professor of Trauma,  
Director Program in Trauma  
University of Maryland School of Medicine  
System Chief for Critical care  
University of Maryland Medical System  
tscalea@umm.edu

170. **MAJ Jo Schmid, BScN, RN, CNCC(C)**  
527 Gardner Cres, Petawawa, ON, K8H 0C4  
Canada  
jschmid817@hotmail.com

171. **Martin A. Schreiber, MD FACS**  
Professor of Surgery  
3181 SW Sam Jackson Park Road, Mail Code L611, Portland, OR 97239  
schreibm@ohsu.edu

172. **C. William Schwab MD, FACS, FRCS (Glas)**  
Emeritus Professor of Surgery  
Perelman School of Medicine  
University of Pennsylvania  
Senior Consultant  
Penn Medicine  
Philadelphia, PA, USA  
Charles.Schwab@uphs.upenn.edu

173. **Beth H Shaz, MD**  
New York Blood Center, CMSO  
310 E 67th St, NY, NY 10065  
bshaz@nybc.org

174. **Forest Sheppard, MD**  
Associate Professor of Surgery  
Acute and Critical Care Surgery  
Department of Surgery  
Washington University  
forest.r.sheppard@wustl.edu
175. Eilat Shinar, MD
   Director, Magen David Adom in Israel
   Tel HaShomer, Israel
   eilats@mda.org.il

176. Cees Th. Smit Sibinga, MD, PhD,FRCPath Edinburgh, FRCPath (London)
   emProfessor of International Development of Quality Management in
   Transfusion Medicine, University of Groningen, Groningen, NL.
   Director IQM Consulting for International Development of Quality Management
   in Transfusion Medicine, Zuidhorn, NL
   c.sibinga@planet.nl

177. Jeffrey Siegler, MD
   EMS Physician, Instructor of Emergency Medicine
   Washington University School of Medicine
   Sieglerj@wustl.edu

178. Christopher C Silliman, MD, PhD
   Professor of Pediatrics and Surgery
   School of Medicine
   University of Colorado Denver
   Senior Independent Investigator
   Research Department
   Bonfils Blood Center
   Attending Physician
   Center for Cancer and Blood Disorders
   Children's Hospital of Colorado
   Christopher.Silliman@ucdenver.edu

179. Sven Chr Skaiaa
   Consultant Anesthesiologist
   University of Oslo, Air Amb dep.
   Stupulvegen 5, 3560 Hemsedal, Norway
   scskaiaa@gmail.com

180. Surgeon Rear Admiral Jan Sommerfelt-Pettersen
   Surgeon Genereal
   Norwegian Defence Joint Medical Service
   Joint Medical Service, N-2058 Sessvollmoen, Norway
   jan@sommerfelt-pettersen.no

181. Jason L. Sperry, MD, MPH
   Professor of Surgery and Critical Care Medicine
   Presbyterian Hospital, Suite F1268, 200 Lothrop Street, Pittsburgh PA 15213
   sperryjl@upmc.edu
182. Philip C. Spinella, MD, FCCM
Professor of Pediatrics, Division of Critical Care Medicine
Director, Critical Care Translational Research Program
Washington University in St. Louis
USA

183. Ulrik Sprogøe, MD, PhD
Deputy Medical Director
Department of Clinical Immunology (part of South Danish Transfusion Service)
Odense University Hospital
DK-5000 Odense C
Denmark
ulrik.sprogoe@rsyd.dk

184. Simon J Stanworth, DPhil MD
Consultant Haematologist
NHS Blood and Transplant/
Oxford University Hospitals NHS Foundation Trust
Level 2, John Radcliffe Hospital
Honorary Senior Clinical Lecturer,
University of Oxford
simon.stanworth@nhsbt.nhs.uk

185. Marie Steiner, MD, MS
Professor, Pediatrics
MMC 484, University of Minnesota, Minneapolis, MN 55455
stein083@umn.edu

186. Zsolt Stockinger, MD, FACS
CAPT, MC, USN
Director, Joint Trauma System/Defence Center of Excellence for Trauma
Associate Professor of Surgery, Uniformed Services University of Health Sciences
3698 Chamber Pass, STE B
JBSA Fort Sam Houston, TX 78234-7767
210-539-9174 DSN 389
zsolt.t.stockinger.mil@mail.mil

187. Geir Strandenes, MD, SMO NORNAVSO
Senior Medical Officer, Norwegian Naval Special Operation Commando Researcher, Department of Immunology and Transfusion Medicine
Haukeland University Hospital
Norway
geir@docfish.no
188. Ronald G. Strauss, MD
Professor Emeritus Departments of Pathology & Pediatrics University of Iowa College of Medicine Associate Medical Director, Associate Medical Director, LifeSource/ITxM
rstrauss@itxm.org

189. Paul Stricker, MD
Associate Professor of Anesthesiology and Critical Care, The Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania
3401 Civic Center Blvd, Philadelphia, PA 19104
strickerp@email.chop.edu

190. James R. Stubbs, MD
Consultant, Department of Laboratory Medicine and Pathology Chair, Division of Transfusion Medicine
Mayo Clinic
200 First Street SW
Rochester, Minnesota, 55905
stubbs.james@mayo.edu

191. Marius Svanevik, MD
Vestfold Hospital Trust (Consultant Gastrointestinal Surgery)
Norwegian Army NorSOST, SMO (OF-3)
drsvanevik@hotmail.com

192. Joseph Sweeney, MD
Director, Transfusion Medicine
Professor, Brown University
The Miriam Hospital
164 Summit Ave
Providence RI 02806
JSweeney@Lifespan.org

193. Matthew Sztajnkrycer, MD, PhD
Associate Professor of Emergency Medicine
Mayo Clinic, Rochester, MN
Sztajnkrycer.Matthew@mayo.edu

194. Lt Cdr Øystein Tandberg, MD
Dept of orthopedics, Haukeland University Hospital, Bergen – Norway
OT HUS, Jonas Lies vei 65, Bergen NO
oystein.tandberg@gmail.com
195. **Patrick Thompson**  
Paramedic  
United Kingdom  
divemedicpatrick@yahoo.co.uk

196. **Isaiah R. Turnbull, MD, PhD**  
Assistant Professor of Surgery  
Department of Surgery  
Barnes-Jewish Hospital  
Washington University Medical Center  
Campus Box 8109  
Saint Louis, Missouri 63110-8109  
iturnbull@wustl.edu

197. **Darrell J. Triulzi, MD**  
Medical Director  
Institute For Transfusion Medicine  
3636 Blvd of the Allies Pittsburgh PA 15213  
Director, Division of Transfusion Medicine  
Department of Pathology  
University of Pittsburgh  
dtriulzi@itxm.org

198. **Gunnar Vangberg, MD, Maj**  
Norwegian Armed Forces Joint Medical Forces  
St. Olavs University Hospital, Trondheim, Norway  
Gunnarvangberg@hotmail.com

199. **Adam M. Vogel, MD, FACS, FAAP**  
Associate Professor, Surgery and Pediatrics Baylor College of Medicine and Texas Children's Hospital  
6701 Fannin Street, Suite 1210 Houston, TX 77030  
adamv@bcm.edu

200. **Ville Voipio, MD, SSAI-ECC**  
HEMS-physician  
Kipinämiäintie 20, Oulu 90420, Finland  
voipio@mac.com

201. **LT COL Jerome Vinluan**  
Deputy for Policy  
US Armed services blood procurement office

202. **Terje Wadahl**  
Nurse Anesthesist  
Head Nurse Norwegian Army/E8  
terje@wadahl.org
203. **Kevin Ward, MD**  
Department of Emergency Medicine  
University of Michigan  
Michigan Center for Integrative Research in Critical Care (MCIRCC)  
USA

204. **Daniel R Walker, MD, MS, FCAP**  
Col, USAF, MC, FS  
Medical Director, Apheresis and Cellular Therapy, San Antonio Military Medical Center  
Medical Director, Armed Services Blood Bank Center - San Antonio  
Assistant Professor of Pathology, Uniformed Services University of the Health Sciences  
clotmeister@outlook.com

205. **Jonathan Wallis, BA. Oxon, MB. BS. Lond, FRCP (UK), FRCPath.**  
Consultant Haematologist  
Head of Blood Transfusion Newcastle upon Tyne Hospitals UK (Regional Major trauma centre)  
Chair of the National Blood Transfusion Committee, England  
President of the British Blood Transfusion Society  
Jonathan.Wallis@nuth.nhs.uk

206. **Elizabeth Waltman, MBA**  
Chief Operating Officer, South Texas Blood and Tissue Center  
Executive Director, Blood and Tissue Center Foundation  
6211 IH-10 West, San Antonio, TX 78201  
elizabeth.waltman@southtexasblood.org

207. **Agneta Wikman, MD, PhD**  
Associate professor  
Karolinska University Hospital and Karolinska Institutet  
Transfusion Medicine L2:01, Karolinska 17176 Stockholm Sweden  
Agneta.wikman@sll.se

208. **Rob Woods, MD MMEd FRCPC**  
Emergency Physician & Trauma Team Leader - Saskatoon Health Region  
STARS Transport Physician  
Assistant Professor & Residency Program Director - Department of Emergency Medicine,  
College of Medicine, University of Saskatchewan  
rob.woods@usask.ca

209. **LT COL Thomas Woolley, FRCA RAMC**  
Defence Senior Lecturer in Trauma Anaesthesia  
UK  
tomwoolley@me.com

210. **Arino Yaguchi**  
Tokyo Women's Medical University  
8-1 Kawadacho, Shinjuku, Tokyo, 1620054, Japan  
ayaguchi@twmu.ac.jp
211. **Vered Yahalom, MD**  
Transfusion & Apheresis Services Director  
Rabin Medical Center, Petah Tikva, Israel  
veredya2@clalit.org.il

212. **Mark Yazer, MD**  
Professor of Pathology, University of Pittsburgh  
Medical Director, RBC serology reference laboratory, Centralized Transfusion Service  
Associate Medical Director, Centralized Transfusion Service  
Adjunct Professor of Clinical Immunology, University of Southern Denmark  
3636 Blvd of the Allies  
Pittsburgh PA 15213  
myazer@itxm.org

213. **LTC Avraham Yitzhak, MD, MHA**  
General Surgeon  
Head of Trauma and Combat Branch  
Israeli Defense Forces Medical Corps headquarters  
Tel Hashomer, Ramat Gan  
Israelyitzhak@gmail.com

214. **Pampee P. Young, MD, PhD**  
Associate Professor  
Medical Director, Transfusion Medicine  
Department of Pathology, Microbiology, immunology  
1161 21st Ave South, MCN C2217  
Vanderbilt University Medical Center  
Nashville, TN 37232  
pampee.young@Vanderbilt.Edu

215. **Nicole Dodge Zantek, MD, PhD**  
University of Minnesota, Associate Professor  
University of Minnesota, 420 Delaware Street SE, MNC 609, Minneapolis, MN 55455  
Zant0005@umn.edu

216. **Martin D. Zielinski, MD, FACS**  
Professor of Surgery  
Medical Director of Trauma Research  
Division of Trauma, Critical Care, and General Surgery  
Department of Surgery  
Mayo Clinic  
200 First Street SW  
Rochester, MN  
55902  
Zielinski.Martin@mayo.edu
217. **Alyssa Ziman, M.D.**

Professor, Pathology and Laboratory Medicine  
Division Chief, Clinical Laboratory Medicine  
Medical Director, Clinical Laboratories, Ronald Reagan UCLA Medical Center  
Medical Director, Transfusion Medicine  
UCLA Health System  
AZiman@mednet.ucla.edu
Proposal to modify Standard 5.15.1 to permit the use of low titer, group O whole blood in massively bleeding patients regardless of their ABO group

Proposal

The AABB/THOR working party (WP) is recommending that the AABB Standards Committee modify standard 5.15.1 to permit the use of low titer, group O whole blood (WB) in all massively bleeding patients regardless of their ABO group. The WP recommends deleting the requirement for administering WB in an ABO-identical manner from 5.15.1, and creating a new standard and substandard as follows:

New standard 1: Low titer, group O whole blood can be administered in an uncrossmatched manner to recipients with a life-threatening hemorrhage regardless of the recipient’s ABO group.

New standard 1.1: Low titer WB shall be defined as <200 for both anti-A and –B.

Background

There is extensive literature and experience indicating that it is desirable and safe to use cold stored, low antibody titer WB early in the management of traumatic hemorrhagic shock.\(^1\) Reports from the Korean war detailed the efficacy and safety of transfusing low titer Group O whole blood; in 1952 over 600,000 units of low titer (defined as <256) group O whole blood were transfused to combat casualties. Patients typically received 10-30 units of low titer, group O WB, and only 4 patients were noted to have post-transfusion hemoglobinuria, which might or might not have been related to the receipt of the WB.\(^1\) During an approximately 18 month period during the Vietnam war, 230,323 WB units were transfused,\(^2\) and only one hemolytic reaction to a group O unit was reported. In fact, this lone, non-fatal reaction
only occurred because a labeled high titer group O unit was accidentally transfused to a group A recipient.\(^3\)

The recent wars in Iraq and Afghanistan have highlighted the high mortality associated with traumatic hemorrhagic shock and provided the opportunity to reevaluate the potential benefits of WB resuscitation in this context. One analysis from Iraq indicated the use of WB was independently associated with improved 30 day survival compared to the use of blood components for US casualties with life-threatening hemorrhage.\(^4\)

Reducing death from hemorrhage is essential since the mortality for patients with traumatic hemorrhagic shock is high (approximately 20%) and there are approximately 30,000 preventable civilian deaths due to traumatic hemorrhage per year in the US alone.\(^5\) The rationale for the use of group O WB early in the resuscitation of massively bleeding patients is multifactorial and has been recently reviewed.\(^5,6\) Group O whole blood provides a balanced resuscitation that simultaneously addresses oxygen debt and coagulopathy, both of which are associated with high mortality in this population.\(^4,7,8\) The use of a blood based transfusion strategy that approximates whole blood with 1:1:1 unit ratios has been shown to reduce death from hemorrhage in adult trauma patients.\(^4,8\) Whole blood is a more concentrated product containing a smaller quantity of anticoagulant and preservative solutions compared to an equivalent amount of reconstituted WB from blood components.\(^4\) The cold stored platelets in WB improve hemostasis more effectively compared to platelet units stored at room temperature (RT).\(^9,10\) Improved hemostasis with platelets stored at 4C has been extensively reviewed and is based on a significant amount of in vitro data and 2 RCTs.\(^9-12\) One RCT in children demonstrated reduced blood loss and improved platelet aggregation in the cold stored whole blood arm compared to those in the conventional components arm who were transfused with RT stored platelets in a 1:1:1 ratio.\(^13\) Another trial of adults on aspirin showed improved correction in the bleeding time when a cold
stored platelet unit was transfused compared to a conventional RT unit. Furthermore, the use of WB will greatly simplify the logistics of the resuscitation by transfusing the contents of one bag instead of up to three bags that all have to be separately procured and transported from the blood bank under different temperature conditions. This latter advantage is especially important in the pre-hospital setting where space in the helicopter or ambulance is at a premium, and often intravenous (IV) access in the patient is limited. The ability to quickly provide a transfusion to traumatically injured patients has been shown to improve outcomes in both military and civilian trials, and it is known that mortality is increased by 5% for every minute that initiating a transfusion was delayed in these patients. Since it is not feasible to transport RBCs, plasma and platelet units in the prehospital setting, the most effective method of resuscitating a patient with traumatic hemorrhagic shock in the prehospital setting is with WB. Effective resuscitation in the prehospital phase of treatment is essential because of the 30,000 preventable deaths per year in the US due to traumatic hemorrhage, approximately 25,000 of these deaths occur in the prehospital phase of resuscitation.

A major limitation to implementing low titer group O WB at civilian medical centers is the AABB standard regarding its use. The AABB’s Standards for Blood Banks and Transfusion Services require that WB units be ABO-identical with the recipient (standard 5.15.1 in the 31st edition of the standards). There is a theoretical concern that a minor incompatible plasma transfusion could lead to hemolysis of the recipient’s RBCs. However, a subsequent standard permits the transfusion of minor incompatible plasma so long as the transfusion service has a policy guiding this practice (standard 5.15.4 in the 31st edition of the standards). According to the latter standard, a minor incompatible transfusion of group O platelets or plasma could be administered to a group A recipient, as long as the transfusion service has a policy that permits this practice. Therefore, there is a circularity in the AABB standards: a transfusion service is permitted to transfuse the minor incompatible plasma in platelets and plasma units, but not from WB. Standard 5.15.4 does not provide guidance on the number of units or the total quantity of
minor incompatible plasma that can be transfused, any specific donor-recipient ABO pairings that are forbidden, what to do with group O minor incompatible units in particular, whether an antibody titer must be performed on the minor incompatible product before it is transfused, or under which clinical circumstances minor incompatible plasma may be transfused – all of this is left to the discretion of the individual transfusion service’s medical director. It therefore remains unclear why the regulation of WB transfusion was specifically excluded from Standard 5.15.4.

The safety of transfusing minor incompatible plasma, mainly through platelet transfusions, is well documented. In 2015, there were nearly 2 million apheresis and whole blood platelet units transfused in the US,18 and in the United Kingdom there were over 300,000 doses issued to hospitals in 2016.19 Many of these transfusions would surely have featured a minor incompatibility between donor and recipient.20 Yet the number of times that recipients experienced a hemolytic episode from the minor incompatible plasma in the platelet dose remains very small, on the order of a few case reports (reviewed in references 21 and 22). Furthermore, in a study of 16 hematology/oncology patients who received at least one ABO-identical and a minor mismatched platelet transfusion within a 24 hour period,23 Mair and Benson found that there was no significant difference in the mean change in hemoglobin concentration following the ABO-identical vs. the minor mismatched platelet transfusions. This indicates that hemolysis did not occur following the transfusion of the minor mismatched platelet unit in spite of the fact that most of the minor incompatible platelets were group O; these units potentially have higher titers of anti-A and/or anti-B compared to platelets from the other blood groups and are considered to be the highest risk product in terms of causing hemolysis following a minor incompatible transfusion. None of these minor incompatible platelet transfusions were shown to contain low titers of anti-A and/or –B, and yet significant hemolysis did not occur. Furthermore, traumatically injured patients are often transfused with large quantities of platelet units. In fact, in the recent PROPPR trial the median number of whole blood platelet units transfused in the high ratio group
was 12 (effectively a double dose of platelets in adults) within the first 24 hours. A double dose of platelets contains approximately 600 ml of potentially minor-incompatible plasma. Thus, it is commonplace to provide traumatically injured patients with large quantities of potentially incompatible plasma.

The safety of the use of group A plasma in trauma (STAT) study demonstrated that group B and AB trauma recipients who received an average of 4 units of group A plasma during their resuscitation did not have increased early- or in-hospital mortality, or longer hospital lengths of stay compared to group A trauma patients who also received group A plasma. There were also no reported acute hemolytic reactions reported amongst these B and AB recipients. Importantly, the vast majority of the participating hospitals in this study (76%) did not titer the anti-B in the plasma and were thus not intentionally providing low titer units to their trauma patients, and yet there were no demonstrably worse outcomes amongst the B and AB recipients who received minor incompatible plasma transfusions compared to those who received fully compatible transfusions.

The safety of using cold stored, low titer (<50 anti-A and –B by manual saline tube immediate spin without enhancements) WB in traumatically injured civilian patients has been demonstrated. In a study of 27 non-group O and 17 group O recipients, there was no laboratory or clinical evidence of hemolysis in the former group compared to the latter group of recipients, with the exception of a higher median level of total bilirubin amongst the non-group O recipients on the day of receipt of WB. This higher median total bilirubin level was still within the normal range, and the difference in this parameter between the group O and non-group O recipients was no longer apparent on the following day. These observations have been extended to include additional recipients, and recipients of greater numbers of WB units (3 and 4 units), and there continues to be no biochemical or clinical evidence of hemolysis amongst the non-group O recipients (M. Yazer, unpublished observations). Furthermore, low titer (<50,
as described above) cold stored group O WB has also been successfully implemented at the Children’s Hospital of Pittsburgh. Traumatically injured children older than 3 years and weighing more than 15 kg can receive up to 30 ml/kg of uncrossmatched group O WB. The non-O pediatric recipients did not demonstrate clinical or laboratory evidence of hemolysis compared to the group O pediatric recipients (data to be presented as an oral abstract at the 2017 AABB annual meeting).

It is interesting to note that the 5 civilian trauma centers or emergency medical systems in the US and Norway that are using group O WB have all adopted an anti-A and anti-B titer threshold of between <50 and <200 to define “low titer”. This could be a reasonable range for blood centers and transfusion services to consider when creating their local definition of a low titer. Thus, as the evidence from the civilian adult and pediatric experience with WB indicates, these low titer group O WB units have an enhanced safety margin compared to untitered minor incompatible plasma that is transfused with non-ABO compatible platelet units. Furthermore, the fact that only low titer WB units are being issued to civilian trauma patients in the US adds yet another layer of safety and reassurance about the safety of using low titer WB in trauma patients regardless of whether their ABO group is known at the time of the transfusion or not.

The safety of transfusing minor incompatible plasma is well established and indeed this practice is permitted in the AABB standards (5.15.4) for all plasma-containing products except WB. However, the transfusion of WB to a recipient of unknown ABO group is prohibited by standard 5.15.1 thereby delaying the administration of this product to some massively bleeding patients. This prohibition is retarding the implementation of civilian pre- and early in-hospital WB transfusion programs. The AABB/THOR working party has generated a petition that has been signed by 217 experts in the fields of transfusion medicine and resuscitation medicine from 24 countries, demonstrating that there is
significant domestic and international interest in using low titer group O WB in traumatically injured patients or in others with life-threatening hemorrhage.

With the growing body of evidence indicating that low titer group O WB is serologically safe for non-O recipients in adults and children, and the increasing support and demand for this product in the US, Standard 5.15.1 should be modified to permit the use of low titer, group O WB in massively bleeding patients regardless of their ABO group. Requiring each individual medical center to submit a variance is an inefficient approach to permitting the use of low titer group O WB. Each transfusion service would also follow Standard 5.15.4 and devise a policy that specifies the definition of low titer, the quantity of group O WB that can be transfused per patient, the nature of massively bleeding patients who would qualify to receive it, and any clinical surveillance of the recipients of this product that may be necessary.


22. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfusion medicine reviews 2003;17: 57-68.


